Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Sponsor
Asociación para Evitar la Ceguera en México
Study ID
NCT00555594
Phase
PHASE2/PHASE3
Status
Completed

Conditions

  • Corneal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To determine the effect of subconjunctival Bevacizumab in corneal neovascularization

Key Dates

First listed
Nov 8, 2007
Start date
Sep 30, 2006
Status verified
Jul 2024
Primary completion
Sep 30, 2006
Completion
Oct 31, 2007

Study Design

Enrollment
18 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: A
    Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
  • Active Comparator: B
    Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.

Primary Outcome Measure

Anterior segment slit-lamp photographs and fluorescein angiograms Compared for any sign of diminished vascularization [ Time Frame: three weeks after treatment ]

Related Studies